A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Issue 1 (22nd July 2021)

• Record Type: Journal Article
• Authors: Klein, Kevin; Borchard, Gerrit; Shah, Vinod P.; Flühmann, Beat; McNeil, Scott E.; de Vlieger, Jon S. B.
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1502:Issue 1(2021)
• Page Start: 5
• Page End: 13
• Publication Date: 2021-07-22
• Subjects: complex drugs -- complex generic drug products -- nonbiological complex drugs -- generics -- follow‐on products -- FDA; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.14662
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract: The diverse nature of complex drug products poses challenges for the development of regulatory guidelines for generic versions. While complexity is not new in medicines, the technical capacity to measure and analyze data has increased. This requires a determination of which measurements and studies are relevant to demonstrate therapeutic equivalence. This paper describes the views of the NBCD Working Group and provides pragmatic solutions for approving complex generics by making best use of existing U.S. Food and Drug Administration's abbreviated approval pathways 505(j) and 505(b)(2). We argue that decisions on the appropriateness of submitting a 505(j) or 505(b)(2) application can build on the FDA's complex drug product classification as well as the FDA's much applauded guidance document for determining whether to submit an ANDA or a 505(b)(2) application. We hope that this paper contributes to the discussions to increase the clarity of regulatory approaches for complex generics, as well as the predictability for complex generic drug developers, to facilitate access to much‐needed complex generics and to promote the sustainability of the healthcare system. Abstract : This paper describes the views of the NBCD Working Group and provides pragmatic solutions for approving complex generics by making best use of existing U.S. FDA's abbreviated approval pathways of 505(j) and 505(b)(2). We argue that decisions on the appropriateness of submitting a 505(j) or 505(b)(2) application can build on the FDA's complex drug product classification as well as the FDA's much applauded guidance document for determining whether to submit an ANDA or a 505(b)(2) application.